These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26553163)

  • 21. Ophthalmic drug discovery.
    Clark AF; Yorio T
    Nat Rev Drug Discov; 2003 Jun; 2(6):448-59. PubMed ID: 12776220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Dick AD; Tundia N; Sorg R; Zhao C; Chao J; Joshi A; Skup M
    Ophthalmology; 2016 Mar; 123(3):655-62. PubMed ID: 26712559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in ocular gene therapy.
    Chung DC; Lee V; Maguire AM
    Curr Opin Ophthalmol; 2009 Sep; 20(5):377-81. PubMed ID: 19667988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ocular disorders and the utility of animal models in the discovery of melatoninergic drugs with therapeutic potential.
    Crooke A; Huete-Toral F; Martínez-Águila A; Colligris B; Pintor J
    Expert Opin Drug Discov; 2012 Oct; 7(10):989-1001. PubMed ID: 22860991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
    Myles ME; Neumann DM; Hill JM
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retina expression and cross-species validation of gene silencing by PF-655, a small interfering RNA against RTP801 for the treatment of ocular disease.
    Lee DU; Huang W; Rittenhouse KD; Jessen B
    J Ocul Pharmacol Ther; 2012 Jun; 28(3):222-30. PubMed ID: 22304497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thermal safety of ultrasound-enhanced ocular drug delivery: A modeling study.
    Nabili M; Geist C; Zderic V
    Med Phys; 2015 Oct; 42(10):5604-15. PubMed ID: 26429235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations.
    Short BG
    Toxicol Pathol; 2008 Jan; 36(1):49-62. PubMed ID: 18337221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis.
    Mruthyunjaya P; Khalatbari D; Yang P; Stinnett S; Tano R; Ashton P; Guo H; Nazzaro M; Jaffe GJ
    Arch Ophthalmol; 2006 Jul; 124(7):1012-8. PubMed ID: 16832025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic applications of ultrasound in ophthalmology.
    Aptel F; Lafon C
    Int J Hyperthermia; 2012; 28(4):405-18. PubMed ID: 22621741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants in normal rabbit and pharmacodynamics in a rat model of choroidal neovascularization.
    Robinson MR; Baffi J; Yuan P; Sung C; Byrnes G; Cox TA; Csaky KG
    Exp Eye Res; 2002 Feb; 74(2):309-17. PubMed ID: 11950241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eclectic Ocular Comorbidities and Systemic Diseases with Eye Involvement: A Review.
    Pinazo-Durán MD; Zanón-Moreno V; García-Medina JJ; Arévalo JF; Gallego-Pinazo R; Nucci C
    Biomed Res Int; 2016; 2016():6215745. PubMed ID: 27051666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The association between cigarette smoking and ocular diseases.
    Cheng AC; Pang CP; Leung AT; Chua JK; Fan DS; Lam DS
    Hong Kong Med J; 2000 Jun; 6(2):195-202. PubMed ID: 10895144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: powerful eye health application technique and therapeutic platform.
    Babizhayev MA
    Drug Test Anal; 2012 Jun; 4(6):468-85. PubMed ID: 21416634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dry eye disease and uveitis: A closer look at immune mechanisms in animal models of two ocular autoimmune diseases.
    Bose T; Diedrichs-Möhring M; Wildner G
    Autoimmun Rev; 2016 Dec; 15(12):1181-1192. PubMed ID: 27639836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ocular health status of rural dwellers in south-western Nigeria.
    Adegbehingbe BO; Majengbasan TO
    Aust J Rural Health; 2007 Aug; 15(4):269-72. PubMed ID: 17617092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delivery of therapeutics for deep-seated ocular conditions - status quo.
    Nguyen H; Eng S; Ngo T; Dass CR
    J Pharm Pharmacol; 2018 Aug; 70(8):994-1001. PubMed ID: 29675844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Measuring patient's quality of life in ophthalmology].
    Hirneiss C; Neubauer AS; Welge-Lüssen U; Eibl K; Kampik A
    Ophthalmologe; 2003 Dec; 100(12):1091-7. PubMed ID: 14704825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [STUDY OF THE ACTION OF 3 SYMPATOMIMETIC AMINES ON EXPERIMENTAL OCULAR HYPERTENSION IN THE RABBIT].
    BONOMI L; RAGNETTI E
    Boll Ocul; 1964 Jun; 43():448-56. PubMed ID: 14258381
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.